

## Trial Description

### Title

**Randomized, multicenter study comparing robot-assisted and conventional laparoscopic radical prostatectomy**

### Trial Acronym

**LAP-01**

### URL of the trial

[---]\*

### Brief Summary in Lay Language

**The objective of the study is the comparison of two surgical techniques for localized prostate cancer (robot-assisted versus non-robot-assisted). Bring the robot-assisted method benefits for the patient. Analyzed are men with localized prostate cancer.**

### Brief Summary in Scientific Language

**Robot-Assisted Laparoscopic Radical Prostatectomy compared to conventional laparoscopic radical prostatectomy in terms of functional, clinical and oncological parameters and quality of life and patient satisfaction.**

### Do you plan to share individual participant data with other researchers?

[---]\*

### Description IPD sharing plan

[---]\*

## Organizational Data

- DRKS-ID: **DRKS00007138**
- Date of Registration in DRKS: **2014/11/13**
- Date of Registration in Partner Registry or other Primary Registry: [---]\*
- Investigator Sponsored/Initiated Trial (IST/IIT): **yes**
- Ethics Approval/Approval of the Ethics Committee: **Approved**
- (leading) Ethics Committee Nr.: **079-12-05032012 , Ethikkommission an der Medizinischen Fakultät der Universität Leipzig**



## Secondary IDs

## Health condition or Problem studied

- ICD10: **C61 - Malignant neoplasm of prostate**

## Interventions/Observational Groups

- Arm 1: **conventional laparoscopic radical prostatectomy**
- Arm 2: **robot-assisted laparoscopic radical prostatectomy**

## Characteristics

- Study Type: **Interventional**
- Study Type Non-Interventional: [---]\*
- Allocation: **Randomized controlled trial**
- Blinding: [---]\*
- Who is blinded: **patient/subject**
- Control: **Active control**
- Purpose: **Other**
- Assignment: **Parallel**
- Phase: **N/A**
- Off-label use (Zulassungsüberschreitende Anwendung eines Arzneimittels): **N/A**

## Primary Outcome

**continence 3 months postoperative (ICIQ=Urinary Incontinence Form, pads, diary)**

## Secondary Outcome

- **Continence (ICIQ-SF): 1, 3, 6, 12 months p.o.**
- **Continence (Pads-per day): 1, 6, 12 months p.o.**
- **Erectile function (IIEF-5): 3, 6, 12 months p.o.**
- **Quality of life (EORTC QLQ-C30): 1, 3, 6, 12 months p.o.**
- **Anxiety and depression (HADS): 1, 3, 6, 12 months p.o.**
- **Satisfaction: 1, 3, 6, 12 months p.o.**
- **PSA: 3, 6, 12, 24, 36**



## Countries of recruitment

- DE **Germany**

## Locations of Recruitment

- University Medical Center **Klinik für Urologie, Düsseldorf**
- University Medical Center **Klinik für Urologie, Heidelberg**
- Medical Center **Klinik für Urologie, Dortmund**

## Recruitment

- Planned/Actual: **Planned**
- (Anticipated or Actual) Date of First Enrollment: **2014/11/17**
- Target Sample Size: **782**
- Monocenter/Multicenter trial: **Multicenter trial**
- National/International: **National**

## Inclusion Criteria

- Gender: **Male**
- Minimum Age: **18 Years**
- Maximum Age: **75 Years**

## Additional Inclusion Criteria

- **Histologically confirmed prostate cancer (diagnosis)**
- **Indication for primary-curative radical prostatectomy**
- **Patients aged  $\leq 75$  years (at the time of surgery)**

## Exclusion criteria

- **Obese patients with a BMI > 35**
- **Currently present severe concomitant disease (eg, Liver cirrhosis, secondary malignancy or recurrence of any kind)**
- **Tumor stage: T4**
- **Previous malignancy ( $\leq 3$  years before inclusion in this study)**
- **Neoadjuvant therapy ( $\leq 3$  months prior to inclusion in this study)**
- **Immune Compromised Patients**
- **Intermittent self-catheterization (in the year prior consent)**
- **The following treatments in the past 3 months: Operations at Sigma, extensive Hämorrhoidalresektion, Transurethral needle ablation of the prostate (TUNA), osteosynthesis supplies the pelvic area, salvage prostatectomy**

- **Patients with chronic urinary tract infection (proven more than 5 antibiotic-requiring infection episodes in last year)**
- **Requiring dialysis patients**

## Addresses

### ■ Primary Sponsor

**Universität Leipzig  
Ritterstraße 26  
04109 Leipzig  
Germany**

Telephone: [---]\*

Fax: [---]\*

E-mail: [---]\*

URL: [---]\*

### ■ Contact for Scientific Queries

**Universitätsklinikum Leipzig Klinik und Poliklinik für Urologie  
Ms. Dr. Sigrun Holze  
Liebigstr. 20  
04103 Leipzig  
Germany**

Telephone: **03419717600**

Fax: [---]\*

E-mail: **LAP-01 at uniklinik-leipzig.de**

URL: [---]\*

### ■ Contact for Public Queries

**Universitätsklinikum Leipzig Klinik und Poliklinik für Urologie  
Ms. Dr. Sigrun Holze  
Liebigstr. 20  
04103 Leipzig  
Germany**

Telephone: **03419717600**

Fax: [---]\*

E-mail: **LAP-01 at uniklinik-leipzig.de**

URL: [---]\*

## Sources of Monetary or Material Support

### ■ Private sponsorship (foundations, study societies, etc.)

**Deutsche Krebshilfe e.V.**

DRKS-ID: **DRKS00007138**

Date of Registration in DRKS: **2014/11/13**

Date of Registration in Partner Registry or other Primary Registry: [---]\*



**Deutsches Register  
Klinischer Studien**

**German Clinical  
Trials Register**

---

**Private sponsorship (foundations, study societies, etc.)**

**Deutsche Krebshilfe e.V.**

**Buschstr. 32**

**53113 Bonn**

**Germany**

Telephone: [---]\*

Fax: [---]\*

E-mail: [---]\*

URL: [---]\*

## Status

- Recruitment Status: **Recruiting ongoing**
- Study Closing (LPLV): [---]\*

## Trial Publications, Results and other documents

*Please note:*

*There are additional attributes available concerning this trial. To open an extended view please [click here](#).*